论文部分内容阅读
Objective To explore the efficacy of Montelukast in prematures with bronchopulmonary dysplasia(BPD)and analyse its effect on the infants development and metabolism.Methods We did this quasi randomized,blinded and prospective trial between January 2016 and October 2017 in the First Affiliated Hospital of Nanjing Medical University and Affiliation Hospital of Jiangsu University.Preterm infants with BPD were allocated into montelukast group and control group.In the montelukast group,prematures were given 1 mg/kg of Montelukast sodium daily when the diagnosis was made.The dosage of montelukast was added to 2 mg/kg daily in the 3rd week,and the maximum dose of the drug was 4mg daily.Detailed clinical data of all infants envolved were documented.Results A total of 38 preterm infants were involved in this study.There were no significant differences in the baseline data of maternal age,gestational age,sex gender,born by cesarean,Apgar score,birth weight,birth length,the incidence of SGA and neonatal asphyxia between two groups(P>0.05).There was also no significant difference in the incidence of moderate or severe BPD(36.8%vs.42.1%)between two groups(P>0.05).The mean duration of mechanical ventilation(MV)(11.33 ±8.54 d vs.10.0 ±9.08 d, P=0.325)were shorter in montelucast group than that in control group.The mean duration of oxygen therapy(44.61 ±24.06 d vs.50.41 ±20.95 d,P=0.221)and the mean hospital stay(56.89±23.42 d vs.61.11 ± 17.84 d,P=0.268)were shorter in montelucast group compared to those in control group.The PSC of montelucast group declined more obviously than that of control group,while the difference didnt vary significantly(P>0.05).There were no significant differences in adverse events between two groups(P>0.05).Conclusion Our study showed that montelukast therapy may shorten the mean duration of oxygen therapy and hospital stay but did not shorten the duration of MV or significantly lighten the severity of BPD.Montelukast therapy in prematures didnt result in any drug-associated adverse events during hospitalization.However,furher studies with large number of cases are required to assess the efficacy of montelukast.